Trials / Unknown
UnknownNCT01270178
Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
Prospective Trial of Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 420 (estimated)
- Sponsor
- Taipei Veterans General Hospital, Taiwan · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Persistent replication of HBV (47-55%) is frequently found in patients with HCC, which in turn leads to deterioration of liver reserve. Moreover, a large proportion of HCC patients who underwent curative therapy died from progressive liver decompensation rather than recurrence of cancer. It had been proved that anti-viral therapy for hepatitis C virus (HCV)-related HCC patients could reduce the rate of tumor recurrence after surgical resection. This is a prospective study to evaluate the efficacy of ETV therapy in chronic hepatitis B patients after receiving RFA therapy for HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entecavir | film coated tablets / 0.5mg / once daily / 3 years |
Timeline
- Start date
- 2011-01-01
- First posted
- 2011-01-05
- Last updated
- 2011-01-05
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01270178. Inclusion in this directory is not an endorsement.